Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer
Alberto Martini(The University of Texas MD Anderson Cancer Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), John P. Sfakianos(Mount Sinai Medical Center), Reza Mehrazin(Icahn School of Medicine at Mount Sinai), Elizabeth R. Plimack(Fox Chase Cancer Center), Rachel Jia(Icahn School of Medicine at Mount Sinai), Sumanta K. Pal(City of Hope), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Lauren C. Harshman(Dana-Farber Cancer Institute), Bart S. Ferket(PragmatIC (United Kingdom)), Madhu Mazumdar(Memorial Sloan Kettering Cancer Center), Ulka N. Vaishampayan(University of Michigan), Simon J. Crabb(University of Southampton), Andrea Necchi(Vita-Salute San Raffaele University), Evan Y. Yu(University of Washington), Nikhil Waingankar(Icahn School of Medicine at Mount Sinai), Thomas Powles(Queen Mary University of London), Peter Wiklund(Unknown)
Cited by 47
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k